A new medicine for uveal melanoma, a rare cancer of the eye, has received a positive opinion from the European Medicines Agency, putting it on course to be the first T cell receptor (TCR) therapy on the market in Europe. Kimmtrak (tebentafusp) is a bispecific protein comprised of a T cell receptor fused to an effector molecule that redirects T cells to cancer cells. The sponsor is Immunocore Holdings Plc which is developing TCR bispecific therapies for cancer as well as for autoimmune and infectious diseases.
